HER2 GENE MUTATION
Clinical trials for HER2 GENE MUTATION explained in plain language.
Never miss a new study
Get alerted when new HER2 GENE MUTATION trials appear
Sign up with your email to follow new studies for HER2 GENE MUTATION, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Promising combo targets aggressive stomach cancer before surgery
Disease control Recruiting nowThis study is testing whether adding two targeted drugs, pembrolizumab and trastuzumab, to standard chemotherapy can improve outcomes for people with HER2+ esophageal or stomach cancer that can be surgically removed. The treatment is given before surgery to shrink the tumor. The …
Matched conditions: HER2 GENE MUTATION
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated May 16, 2026 22:28 UTC
-
Radioactive antibody targets Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis early-phase study tests a new drug called 177Lu-RAD202, which is a radioactive antibody that seeks out and attaches to HER2 proteins on cancer cells. The goal is to see if it is safe and to find the right dose for people with advanced solid tumors that have not responded to …
Matched conditions: HER2 GENE MUTATION
Phase: EARLY_PHASE1 • Sponsor: Radiopharm Theranostics, Ltd • Aim: Disease control
Last updated May 16, 2026 22:27 UTC
-
New combo aims to stop rare HER2-positive salivary gland cancer in its tracks
Disease control Recruiting nowThis study tests whether adding the targeted drug T-DM1 to standard chemoradiation can keep HER2-positive salivary gland cancer from returning. About 37 people with advanced but removable tumors will receive the drug after surgery. Researchers will track how many remain cancer-fr…
Matched conditions: HER2 GENE MUTATION
Phase: PHASE2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated May 15, 2026 11:56 UTC
-
New combo aims to outsmart resistant stomach cancers
Disease control Recruiting nowThis early-phase trial tests a combination of two targeted drugs, neratinib and fam-trastuzumab deruxtecan (Enhertu), in people with advanced stomach, esophageal, or other gastrointestinal cancers that have a specific marker called HER2. Participants must have already tried at le…
Matched conditions: HER2 GENE MUTATION
Phase: PHASE1 • Sponsor: Fox Chase Cancer Center • Aim: Disease control
Last updated May 05, 2026 11:55 UTC